Article
Multidisciplinary Sciences
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger, N. Ponde, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J. M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M. S. Ewer, S. Dent, C. Plummer, T. Suter
Summary: This study analyzed the cardiac safety of dual blockade with Pertuzumab and Trastuzumab in HER2-positive early breast cancer patients. The results showed that the use of Pertuzumab and Trastuzumab together did not increase the risk of cardiac events compared to Trastuzumab alone. Therefore, non-anthracycline chemotherapy may be considered in patients with cardiovascular risk factors.
Article
Multidisciplinary Sciences
Nina E. Weisser, Mario Sanches, Eric Escobar-Cabrera, Jason O'Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne, Antonios Samiotakis, Andrea Hernandez Rojas, Gesa Volkers, Jodi Wong, Claire E. Atkinson, Jason Baardsnes, Liam J. Worrall, Duncan Browman, Emma E. Smith, Priya Baichoo, Chi Wing Cheng, Joy Guedia, Sohyeong Kang, Abhishek Mukhopadhyay, Lisa Newhook, Anders Ohrn, Prajwal Raghunatha, Matteo Zago-Schmitt, Joseph D. Schrag, Joel Smith, Patricia Zwierzchowski, Joshua M. Scurll, Vincent Fung, Sonia Black, Natalie C. J. Strynadka, Michael R. Gold, Leonard G. Presta, Gordon Ng, Surjit Dixit
Summary: In this study, the authors engineered an anti-HER2 biparatopic antibody, zanidatamab, with multiple mechanisms of action, including induction of HER2 clustering to trigger complement-dependent cytotoxicity, signal inhibition, antibody-dependent cellular cytotoxicity, and phagocytosis. Zanidatamab showed superior in vivo antitumor activity compared to tras + pert in a HER2-expressing xenograft model.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang
Summary: This study compared the efficacy and safety between novel anti-human epidermal growth factor receptor 2 antibody-drug conjugates (ADCs) and trastuzumab emtansine for patients with tyrosine kinase inhibitor (TKI) treatment failure. The results showed that both T-Dxd and other novel anti-HER2 ADCs had significantly better progression-free survival and objective response rate than T-DM1, with tolerable toxicities.
Article
Biochemistry & Molecular Biology
Victor L. Cruz, Virginia Souza-Egipsy, Maria Gion, Jose Perez-Garcia, Javier Cortes, Javier Ramos, Juan F. Vega
Summary: The binding affinity of trastuzumab and pertuzumab to HER2 was studied using experimental and computational methods. The experiments were conducted using complete IgG antibodies and the extracellular domain of HER2 in solution. The results showed that pertuzumab had slightly higher binding affinity than trastuzumab, possibly due to different interfacial contact descriptors. Furthermore, the experiments revealed that pertuzumab preferred to bind to two HER2 proteins, while trastuzumab mainly formed a monovalent complex, possibly due to steric crowding.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jessica Pougoue Ketchemen, Hanan Babeker, Anjong Florence Tikum, Anand Krishnan Nambisan, Fabrice Ngoh Njotu, Emmanuel Nwangele, Humphrey Fonge
Summary: Two domain-specific ADCs were developed and characterized in this study. The combination of these ADCs showed additive benefits, with lower IC50 and higher pharmacokinetics, indicating improved therapeutic effects against HER2.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea P. Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario E. Lacouture
Summary: This retrospective analysis examined the occurrence of pruritus in HER2 + breast cancer patients receiving trastuzumab and pertuzumab treatment. The results showed that pruritus was rare but could occur at different times after treatment initiation and mainly affected the upper extremities, back, lower extremities, and shoulders. Most cases of pruritus were grade 1/2, and patients responded well to treatment with topical steroids, antihistamines, emollients, and gabapentinoids. A small number of patients required treatment interruption or discontinuation.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Summary: This study analyzed the safety and effectiveness data of pertuzumab in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia. The results revealed that pertuzumab showed effectiveness in surgical outcomes and the safety data align with previous clinical trials, without any new safety concerns.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Chau Dang, Michael S. Ewer, Suzette Delaloge, Jean-Marc Ferrero, Ramon Colomer, Luis de la Cruz-Merino, Theresa L. Werner, Katherine Dadswell, Mark Verrill, Daniel Eiger, Sriparna Sarkar, Sanne Lysbet de Haas, Eleonora Restuccia, Sandra M. Swain
Summary: The BERENICE study assessed the cardiac safety of neoadjuvant-adjuvant therapy for high-risk, HER2-positive early breast cancer. The study confirmed that pertuzumab-trastuzumab-based therapies are the standard of care for this patient population, with no new cardiac issues reported.
Article
Oncology
Thibaut Sanglier, Alessandra Fabi, Carlos Flores, Evelyn M. Flahavan, Claudia Pena-Murillo, Anne-Marie Meyer, Filippo Montemurro
Summary: Real-world studies suggest that trastuzumab emtansine (T-DM1) may be less effective in patients with metastatic breast cancer who have received prior pertuzumab treatment. However, these studies may have been biased towards selecting patients with more aggressive disease. Our study evaluated the impact of this selection bias and found that patients who entered the study earlier had poorer outcomes compared to those who entered more recently, indicating that selection bias should be considered in treatment assessments.
Article
Oncology
Antoinette R. Tan, Seock-Ah Im, Andre Mattar, Ramon Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De laurentiis, Jean-Yves Pierga, Kyung Hae Jung, Christian Schem, Alexandra Hogea, Tanja Badovinac Crnjevic, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Christian Jackisch
Summary: The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has been shown to be non-inferior to intravenous administration in terms of efficacy, leading to FDA approval. Safety profile is similar to other studies involving pertuzumab, trastuzumab, and chemotherapy. Ongoing follow-up is focused on long-term outcomes and safety.
Article
Oncology
Amelie Aboudaram, Pierre Loap, Delphine Loirat, Syrine Ben Dhia, Kim Cao, Alain Fourquet, Youlia Kirova
Summary: The study shows that the combination of locoregional breast radiotherapy with dual HER2 blockade of Pertuzumab and Trastuzumab was well tolerated in metastatic breast cancer patients, suggesting that radiotherapy can be safely administered to HER2-positive breast cancer patients.
Article
Oncology
M. J. M. Uijen, G. Lassche, A. C. H. van Engen-van Grunsven, C. M. L. Driessen, C. M. L. van Herpen
Summary: This study presents the results of treating recurrent or metastatic HER2-positive SDC patients with DTP as first-line therapy and subsequently using T-DM1 as second-line therapy. The study found that DTP led to a significant response in some patients, and continuing treatment with T-DM1 upon progression also resulted in a certain level of response. Additionally, potential biomarkers were identified in the study.
Review
Oncology
Daniel Eiger, Elisa Agostinetto, Rita Saude-Conde, Evandro de Azambuja
Summary: The article discusses the expression of HER2 in breast cancer and the development of drugs targeting HER2. Patients with HER2-positive breast cancer have higher chances of cure and survival, and now there are also treatments available for patients with lower levels of HER2 expression.